Login
Immuneering Corp logo

Immuneering Corp

Compare classes
immuneering.com

What Do They Do?

Develops experimental cancer medicines, including atebimetinib and envometinib, for patients with solid tumors.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
โ–ผ โˆ’62% (Loss)
vs โˆ’$15M in Q3 FY2025
  • Jun 1, 2026 Immuneering reported updated trial results and revised development milestones. It reported updated results from its pancreatic cancer trial and anticipated a Phase 3 data readout in mid-2028.

From services to drug development The older report describes computational biology partnerships alongside internally developed drug programs. The latest report says the company ceased its computational biology services business and has focused exclusively on its own research and development programs.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support